Pediatric Surgery

Suzuki Tatsuya

  (鈴木 達也)

Profile Information

Affiliation
教授, 医学部 医学科 小児外科学, 藤田医科大学
Degree
博士(医学)

J-GLOBAL ID
200901042339226272
researchmap Member ID
5000030080

Papers

 115
  • Shunsuke Watanabe, Mikihiro Inoue, Tatsuya Suzuki, Yasuhiro Kondo, Mika Murayama
    Pediatric surgery international, 39(1) 196-196, May 9, 2023  
    BACKGROUND: We previously reported that polyphyllin D, the main component of the traditional herbal medicinal Paris polyphylla, exhibited anticancer effects in vitro against human neuroblastoma cells. The aim of this investigation was to examine in vivo antitumor effects of polyphyllin D. METHODS: Subcutaneous tumors were established in immune-deficient BALB/c nude mice using human neuroblastoma cell lines IMR-32 and LA-N-2. To evaluate the polyphyllin D activity, we used a mouse model of IMR-32 or LA-N-2 cell lines and analyzed subcutaneous tumors. RESULTS: Subcutaneous tumor models were successfully established in mice using two human neuroblastoma cell lines. In the subcutaneous tumor model, porphyrin D was found to suppress tumor volume. We found that polyphyllin D suppressed the number of foci by Ki-67 staining (IMR-32 and LA-N-2; p < 0.01, 0.02, respectively). We found that polyphyllin D induces the RIPK3 expression, while polyphyllin D phosphorylates Ser358 in IMR-32 and Ser358 and Tyr376 in LA-N-2. CONCLUSION: We developed a mouse model of subcutaneous tumors of neuroblastoma and demonstrated for the first time that polyphyllin D has an antitumor effect on neuroblastoma. Polyphyllin D can cause necroptosis depending on the cell type. The new drug can be expected by investigating a method to selectively induce cell death through the analysis of necroptosis.
  • 渡邉 俊介, 井上 幹大, 村山 未佳, 土屋 智寛, 近藤 靖浩, 直江 篤樹, 安井 稔博, 鈴木 達也
    日本小児血液・がん学会雑誌, 59(2) 211-211, Jul, 2022  
  • 土屋 智寛, 村山 未佳, 近藤 靖浩, 直江 篤樹, 渡邉 俊介, 安井 稔博, 井上 幹大, 鈴木 達也
    日本小児外科学会雑誌, 58(2) 209-209, Apr, 2022  
  • 直江 篤樹, 安井 稔博, 土屋 智寛, 村山 未佳, 近藤 靖浩, 渡邉 俊介, 井上 幹大, 鈴木 達也
    日本小児外科学会雑誌, 58(2) 210-210, Apr, 2022  
  • 渡邉 俊介, 井上 幹大, 村山 未佳, 土屋 智寛, 近藤 靖浩, 直江 篤樹, 安井 稔博, 鈴木 達也
    日本小児外科学会雑誌, 58(3) 558-558, Apr, 2022  

Misc.

 31
  • Atsuki Naoe, Tomonori Tsuchiya, Yasuhiro Kondo, Naoko Uga, Shunsuke Watanabe, Toshihiro Yasui, Fujio Hara, Tatsuya Suzuki
    Pediatric surgery international, 35(6) 723-728, Jun, 2019  
    PURPOSE: Arctigenin has been shown to have anti-tumor effects in various types of cancers. This study was conducted to verify these effects in the human-derived hepatoblastoma cell line, HUH-6 clone 5 (hereinafter, HUH-6). METHODS: Arctigenin was added to cultured HUH-6 cells, and cellular activity was evaluated by MTS assay. To determine the relationship between reduced cellular activity and apoptosis, we measured the activities of caspase 3/7, 8, and 9 and conducted flow cytometry with Annexin V/PI staining. RESULTS: The MTS assay revealed that cellular activity decreased after arctigenin treatment in a concentration-dependent manner (IC50 = 4 µM). To investigate apoptosis induction, activity assays of caspase 3/7, 8, and 9 were performed. While caspase 3/7 and 8 exhibited high activity, caspase 9 showed no activity. Thus, apoptosis induction may have involved the action of tumor necrosis factor receptor 1 (TNFR1). Flow cytometry conducted with Annexin V/PI staining revealed the occurrence of early apoptosis. CONCLUSION: We found that arctigenin has anti-tumor effects in HUH-6 cells in a concentration-dependent manner. Arctigenin may have exerted its anti-tumor effect by inducing apoptosis via TNFR1, which recruits Complex IIa to activate caspase 8 and 3/7. These results may be useful for developing therapeutic agents for hepatoblastoma.
  • 宇賀 菜緒子, 土屋 智寛, 近藤 靖浩, 直江 篤樹, 渡邉 俊介, 安井 稔博, 原 普二夫, 鈴木 達也, 中谷 直史, 土田 邦博, 吉村 文, 熊本 海生航, 長尾 静子
    日本小児外科学会雑誌, 55(3) 674-674, May, 2019  
  • Shunsuke Watanabe, Tatsuya Suzuki, Yasuhiro Kondo, Atsuki Naoe, Naoko Uga, Toshihiro Yasui, Fujio Hara, Tomonori Tsuchiya
    Minerva pediatrica, Jan 2, 2019  
    BACKGROUND: Neuroblastoma (NB) is a pediatric malignant solid tumor characterized as refractory cancer with poor prognosis. Mitosis-karyorrhexis index (MKI) is a prognostic factor but is prone to observer bias. The usefulness of MKI with Ki-67, as a marker of malignancy, was investigated. The efficacy of molecular-targeted therapeutic agents with fewer side effects in tumors has been studied. Molecular-targeted therapy targets include vascular endothelial growth factor (VEGF), involved in tumor angiogenesis; c-Kit, receptor of Kit/stem cells involved in tumor growth, vasculature, and lymphangiogenesis; platelet-derived growth factor receptor (PDGFR); and B-Raf proto-oncogene, serine/threonine kinase (BRAF), involved in the RAS protein-mediated mitogen-activated protein kinase pathway. Therefore, expression profiles of these factors and growth inhibitory effects of molecular-targeted drugs against NB were investigated. METHODS: Ten frozen NB tissue samples collected during January 1993-December 2017 were evaluated immunohistochemically for Ki-67 and VEGF. c-Kit, PDGFR, and BRAF expression levels were evaluated using enzyme-linked immunosorbent assays; relationships between these factors and clinicopathological parameters of NB were analyzed. RESULTS: Eight patients with NB showed no amplification of MYCN (MYCN proto- oncogene, bHLH transcription factor). There were two cases of ganglioneuroblastoma (GNB). More NB cells were positive for Ki-67 than for GNB cells. VEGF expression was observed in all NB specimens and was stronger in stage IIB and higher. No BRAF or c-Kit activity was observed; PDGFR activity was greater in NB than in GNB (p = 0.02). CONCLUSIONS: Thus, Ki-67 may help evaluate NB malignancy. As the first therapy for NB prevents amplification of MYCN, agents targeting PDGFR as well as VGFG can inhibit NB cell proliferation.
  • Toshihiro Yasui, Tatsuya Suzuki, Fujio Hara, Shunsuke Watanabe, Naoko Uga, Atsuki Naoe, Yasuhiro Kondo
    Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation, 16(6) 708-713, Dec, 2018  
    OBJECTIVES: In pediatric patients, renal dysfunction after living-donor liver transplant is a major issue that is difficult to evaluate. Recently, predictive equations for Japanese children have been introduced. MATERIALS AND METHODS: We conducted a retrospective study by prospectively collecting data on 26 patients under 16 years old who underwent living-donor liver transplant between June 2004 and March 2015. Serum creatinine and cystatin C levels were measured. Paired t tests and Bland-Altman plots were used to compare the following formulas for estimated glomerular filtration rate: the Schwartz formula and 3 formulas that were matched with Japanese children (polynomial, simple, and cystatin C formulas). RESULTS: Average estimated glomerular filtrations rates (in mL/min/1.73 m2) were 143.46, 122.90, 121.58, and 123.31 using the Schwartz, polynomial, simple, and cystatin C formulas, respectively. The estimated glomerular filtrations rate for biliary atresia was 141.53 ± 31.37 versus 109.95 ± 19.52 for other diseases, with significant differences only noted with the cystatin C formula. The formulas tailored for Japanese children showed significantly lower estimated glomerular filtrations rates than those obtained using the Schwartz formula (P < .01). CONCLUSIONS: The use of formulas for measuring estimated glomerular filtrations rates that are based on race may allow early detection of deteriorating renal function.
  • 水谷 修平, 星野 伸, 竹内 陽平, 隈井 すみれ, 尾池 直子, 奥村 俊彦, 前田 徹, 小林 貴江, 足達 武憲, 小出 照子, 河邊 太加志, 横井 克幸, 中島 葉子, 伊藤 哲哉, 安井 稔博, 鈴木 達也
    日本小児科学会雑誌, 122(1) 118-118, Jan, 2018  

Books and Other Publications

 7

Presentations

 26

Research Projects

 4